Inhibition of central angiotensin-converting enzyme with enalapril protects the brain from ischemia/reperfusion injury in normotensive rat

Author(s):
Message:
Abstract:
Background and the Purpose of the study: Central Angiotensin Converting Enzyme (ACE) has an important role on cerebral microcirculation and metabolism. However، its role in terms of protecting the brain from ischemic/reperfusion (I/R) injury are debatable. This study evaluated the role of ACE، using enalapril as ACE inhibitor، in protection of the brain from I/R injury during transient focal cerebral ischemia (TFCI) in normotensive rat.
Method
Male Sprague Dawley rats (280-320g) randomly assigned to control ischemic and enalapril pre-treated ischemic groups. Enalapril was injected intraperitoneally 1 h before middle cerebral artery occlusion (MCAO) at the dose of 0. 03 or 0. 1 mg/kg. Cerebral ischemia was induced by 60 min MCAO followed by 24 hrs reperfusion. After evaluation of neurological deficit scores (NDS) the animal was sacrificed for assessment of cerebral infarction and edema.
Results
TFCI induced cerebral infarctions (283±18 mm3)، brain edema (4. 1±0. 4%) and swelling (9. 8±1. 5%) with NDS of 3. 11±0. 36. Non-hypotensive dose of enalapril (0. 03 mg/kg) improved NDS (1. 37±0. 26)، reduced cerebral infarction (45%)، brain edema (54%) and swelling of the lesioned hemispheres (34%) significantly. However، hypotensive dose of enalapril (0. 1 mg/kg) could improve neurological activity (1. 67±0. 31) and failed to reduce cerebral infarction (276±39mm3) and swelling (10. 4±1. 4%).
Conclusion
In the rat model of transient focal cerebral ischemia، inhibition of angiotensin converting enzyme with non-hypotensive doses of enalapril has the benefit of improving neurological activity، reducing cerebral infarction، brain swelling and edema of acute ischemic stroke. Therefore، it is reasonable to conclude that central renin-angiotensin system may participate in ischemic/reperfusion injury of the cerebral cortex.
Language:
English
Published:
DARU, Journal of Pharmaceutical Sciences, Volume:18 Issue: 1, Spring 2010
Pages:
35 to 40
magiran.com/p711257  
دانلود و مطالعه متن این مقاله با یکی از روشهای زیر امکان پذیر است:
اشتراک شخصی
با عضویت و پرداخت آنلاین حق اشتراک یک‌ساله به مبلغ 1,390,000ريال می‌توانید 70 عنوان مطلب دانلود کنید!
اشتراک سازمانی
به کتابخانه دانشگاه یا محل کار خود پیشنهاد کنید تا اشتراک سازمانی این پایگاه را برای دسترسی نامحدود همه کاربران به متن مطالب تهیه نمایند!
توجه!
  • حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران می‌شود.
  • پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانه‌های چاپی و دیجیتال را به کاربر نمی‌دهد.
In order to view content subscription is required

Personal subscription
Subscribe magiran.com for 70 € euros via PayPal and download 70 articles during a year.
Organization subscription
Please contact us to subscribe your university or library for unlimited access!